Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB1211 and atezolizumab combination
- Development stage
- Phase 2
- Lead developer
- Damora Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
The combination of GB1211 and atezolizumab represents an innovative approach to cancer treatment, particularly for non-small cell lung cancer (NSCLC). This combination therapy pairs GB1211, an oral small molecule galectin-3 inhibitor developed by Galecto, with atezolizumab (Tecentriq®), a PD-L1 checkpoint inhibitor manufactured by Roche. The therapy aims to overcome resistance mechanisms to checkpoint inhibitors by addressing galectin-3-mediated interference with PD-1/PD-L1 binding, thereby restoring the effectiveness of checkpoint inhibitors.
- Brand names
- Tecentriq®
02
Targets
LGALS3 (Galectin-3)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on GB1211 and atezolizumab combination.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GB1211 and atezolizumab combination.